Introduction

receptors.
The renin-angiotensin system plays a fundamental ACE inhibitors have been successfully used as role in the maintenance and regulation of the extraantihypertensive therapy for more than a decade cellular fluid volume and blood pressure (BP).
1 Conand have been shown to be effective and well tolertrol of BP in essential hypertension can be achieved ated. 2, 3 However, ACE acts on substrates other than by blockade of the renin-angiotensin system. This angiotensin I and its inhibition leads to the accumucan be done either through inhibition of angiotenlation of other polypeptides such as bradykinin and sin-converting enzyme (ACE) or by preventing substance P. These mediators are thought possibly to be responsible for the characteristic side effects associated with ACE inhibitor therapy. 4 Angioneur-
The newest class of antihypertensive agents, cebo run-in period, volunteers satisfying the inclusion criteria were randomised to receive either angiotensin II receptor antagonists, antagonise the action of angiotensin II at its AT 1 cellular receptor valsartan 80 mg, (two groups), lisinopril 10 mg or placebo once daily. Randomisation was stratified by site. [9] [10] [11] As this mode of action does not involve inhibition of the converting enzyme this class would age (Ͻ65 years and у65 years) to provide comparable age distributions for each of the four treatment be anticipated to be effective an antihypertensive devoid of the characteristic ACE inhibitor associated groups within each centre. After 4 weeks on starting dose, those with a mean side effects.
Valsartan is a new, orally active, potent, selective SDBP у90 mm Hg and no symptoms of orthostatic hypotension had their dose of trial medication and specific angiotensin II receptor antagonist. 12 It has already been shown to be effective and well toltitrated upwards according to the following dosage schedules: valsartan 80 mg titrated to valsartan erated when given as a single daily dose of 80 mg regardless of age, sex or race of the study subject. 13 160 mg once daily or to valsartan 80 mg twice daily; lisinopril 10 mg titrated to lisinopril 20 mg once Valsartan demonstrates relatively simple pharmacokinetics and is not dependent on metabolism for daily; placebo to placebo. All other volunteers continued their initial treatment regimen. its activity. It is rapidly absorbed from the gastrointestinal tract with peak plasma valsartan levels
To maintain blinding following titration, all volunteers took two tablets per day, one at approxioccurring approximately 2 h after ingestion. It has an elimination half-life of around 9 h and undergoes mately 8 am and one at approximately 8 pm (active or matching placebo, depending on the dosage little metabolism with the majority excreted as unchanged compound in urine and bile.
14,15 regimen). No medication was taken on the day of the visit, prior to assessment, to provide trough The purpose of the current optional titration trial was to evaluate different treatment regimens for valmeasurement of BP.
After the placebo run-in period, volunteers were sartan in a clinical setting compared to usual treatment regimens with lisinopril. The efficacy, safety seen at 4-week intervals for 12 weeks. At each visit, sitting systolic (SSBP) and SDBP were measured in and tolerability of valsartan 80 mg once daily and valsartan 160 mg daily administered either as a sinaccordance with WHO guidelines (three measurements after 5 min resting, one measurement in the gle dose or as 80 mg twice daily were compared to lisinopril 10 or 20 mg once a day and placebo over standing position after at least 2 min equilibration.) 11 All measurements were to the neara 12-week period.
est 2 mm Hg. Phase V (disappearance of the Korotkoff sound) was used for the measurement of DBP
Materials and methods
in the dominant arm by the same clinician using the Volunteers same mercury sphygmomanometer in the same volunteer. Men and women aged 21-80, with stage I-III diaPulse rate was also measured at each visit and a stolic essential hypertension, were eligible to parphysical examination was performed. In addition, ticipate in the study. Stage I-III hypertension was the occurrence and details of any adverse experidefined as sitting diastolic blood pressure (SDBP) ences were recorded at each visit. Standard labora-у95 mm Hg and р115 mm Hg after 2 to 4 week platory analyses (haematology, blood chemistry, cebo run-in period. The most important exclusion urinalysis) were carried out at baseline and at the criteria were presence of symptomatic heart failure; final visit (12 weeks). myocardial infarction, hypertensive encephalopathy
The use of concomitant medication with the or cerebrovascular accident within the preceding 6 potential to interfere with the assessment of trial months; second or third degree heart block; conendpoints was prohibited throughout the trial. comitant angina pectoris; clinically relevant These concomitant medications included other antiarrhythmias; clinically significant valvular heart dishypertensive drugs, antiarrhythmic drugs, antiease; significant hepatic disease and/or renal impairanginal or heart failure medication, antidepressants, ment, and insulin-dependent diabetes. Women of psychotrophic drugs (except for hypnotics and anxichild-bearing potential were required to use an olytics if the need was present before the trial), and effective form of contraception and to have negative anti-inflammatory drugs apart from aspirin at a pregnancy tests throughout the trial. maximum daily dose of 325 mg. Oestrogen replaceAll volunteers gave written consent to participate ment therapy and thyroid replacement medications in the study which was approved by the relevant were excluded unless the patient had been mainlocal Institutional Review Boards. The study was tained on a stable dose for at least 6 months prior conducted according to the revised Declaration of to study entry. Helsinki and Good Clinical Practice requirements.
The primary efficacy variable was the change from Volunteers could be withdrawn from the trial if baseline in mean SDBP. Other efficacy variables either the patient or the investigator felt it was in included change in SSBP and the presence of a 'sucthe volunteer's best interest to discontinue particicessful' response, defined as mean SDBP Ͻ90 pation in the trial.
mm Hg or у10 mm Hg decrease from baseline. The criteria for tolerability were incidence and Study design type of adverse experiences, significant changes or trends in physical findings, pulse rate and changes The study was a multicentre, randomised, doubleblind, parallel group trial. After a 2 to 4 week plain clinical laboratory parameters. Particular atten-tion was paid to incidence of cough, and clinically The mean duration of treatment, defined as the number of days from randomisation date to the last significant symptomatic postural decreases in BP, defined as a decrease of у20 mm Hg in SBP and/or known medication date (inclusive), was comparable for all four groups (81 days for valsartan 80/160 once a decrease of у10 mm Hg in DBP, accompanied by symptoms of cerebral hypoperfusion, after a posdaily; 82.2 days for valsartan 80/80 twice daily; 81.3 days for lisinopril 10/20 once daily; and 76.8 days tural change from sitting to standing for 2 min. 16 for placebo).
There were a total of 90 premature discontinuStatistical methodology ations during the trial. Most discontinuations were We calculated that at least 180 patients per treatdue to an adverse experience or unsatisfactory therament group would be required to detect a treatment peutic response with the highest proportion for both difference of 3 mm Hg in mean SDBP between the seen in the placebo group. The remainder were due groups with 90% power, assuming a standard devito non-compliance, withdrawal of consent, and lost ation of SDBP of 8 mm Hg.
to follow-up. All randomised volunteers (n = 734) The primary dataset used included all randomised were included in the endpoint dataset, 665 volunpatients with a baseline measurement and at least teers were included in the assessable volunteer dataone post-treatment observation (the intent-to-treat set. Of the 69 volunteers excluded from the clinidataset). In addition, an acceptable patient dataset cally assessable volunteer efficacy analysis, 18 were was used for analyses which included all randomdue to protocol violations. ised volunteers with assessable data who took trial medication for at least 25 days but excluded major protocol violators. For analyses at 4-and 12-week Efficacy time points, all randomised volunteers with a baseline measurement and a measurement at the time All active treatments were significantly superior to point under analysis were included. To avoid potenplacebo in reducing SDBP and SSBP at all time tial analysis problems due to small centres, for each points post dose. Results are given below for the variable small centres were pooled to provide at intent-to-treat dataset unless otherwise stated. Howleast 2 randomised patients with available measureever, results using the acceptable volunteer dataset ments per treatment group for each dataset.
were comparable. Mean SDBP and SSBP were compared by means All three active treatment groups showed signifiof a two-way analysis of covariance (with treatment cantly greater lowering of mean SDBP compared to group and trial centre as factors and baseline as placebo at endpoint (least mean square change from covariate). Both treatment-by-centre and treatmentbaseline: −8.29 mm Hg for valsartan 80/160 once by-baseline interactions were included in the model. daily, −8.67 mm Hg for valsartan 80/80 twice daily, The proportion of successful responders was ana-−9.97 mm Hg for lisinopril 10/20 once daily, −3.04 lysed by means of a one-way logistic model with mm Hg for placebo). Table 2 shows the betweentreatment as the factor. All statistical tests were twotreatment contrasts and shows that the differences sided. Bonferroni's multiple comparison procedure compared to placebo reached statistical significance was used to maintain an overall significance level for all active treatments (P Ͻ 0.001). The three active р0.05. The significance level for each of the pairtreatment groups produced comparable efficacy in wise comparisons was 0.025. reducing mean SDBP with no statistically significant For all safety and tolerability parameters, sumdifferences between active treatments at endpoint mary statistics were used. Frequency of adverse of therapy. experiences by dosage were based on the total daily In the subset of volunteers who were titrated from dose received by the volunteer at the time any valsartan 80 to either valsartan 160 once daily (n = adverse experience began. 114) or valsartan 80 twice daily (n = 124) there was no difference (P = 0.896) between the two regimens of valsartan 160 mg at endpoint (least mean square
Results
reduction in SDBP from baseline −7.90 mm Hg for Patients valsartan 80 twice daily and −7.76 mm Hg for valsartan 160 once daily). A total of 734 hypertensives were randomised into each of the four treatment groups: valsartan 80/160 Figures 1 and 2 show the least mean square reductions in BP at 4 and 12 weeks. At 4 weeks, once daily (n = 177), valsartan 80/80 twice daily (n = 187), lisinopril 10/20 once daily (n = 187) and plawhen volunteers were receiving either valsartan 80 mg once daily, lisinopril 10 mg once daily or placebo (n = 183). A total of 644 patients completed the 12-week study period. Demographics and baseline cebo, both active treatments were significantly superior in lowering SDBP compared to placebo data were similar in the four treatment groups with no statistically significant differences with respect (least mean square change from baseline: valsartan 80 mg, −7.12 mm Hg; lisinopril 10 mg, −7.47 mm Hg; to any of the demographic and medical history variables (Table 1) . Approximately 40% were women placebo, −3.23 mm Hg). The estimated treatment differences compared to placebo were −3.89 mm Hg for and 14% black subjects. The number of patients requiring titration at 4 weeks was highest in the plavalsartan 80 mg (CI −5.40, −2.38; P Ͻ 0.001) and −4.24 mm Hg for lisinopril 10 mg (CI −5.98, −2.51; cebo group (n = 142) compared with valsartan 80/80 twice daily (n = 124), valsartan 80/160 (n = 114) and P Ͻ 0.001). There was no significant difference between the efficacy of valsartan 80 mg once daily lisinopril 10/20 (n = 120). compared to lisinopril 10 mg once daily (estimated (Table 3 ). In the between-treatment comparison for successful responders, there were no significant difdifference 0.35 mm Hg; CI − 1.15, 1.86; P = 0.599).
Results at 12 weeks of therapy were similar to the ferences between active treatment groups at any time point apart from a slightly higher percentage of data for 4 weeks; all active treatments were again significantly superior to placebo (P Ͻ 0.001) with no responders in the lisinopril 10/20 group compared to the valsartan 80/160 group at endpoint (P = 0.012) significant differences between active treatment groups.
and at 12 weeks (P = 0.018). No statistically significant treatment differences between the two valsartan Results for mean SSBP were similar to the findings for mean SDBP (Figures 1 and 2) . All active titrated sub-groups was detected (P = 0.481). treatments were superior to placebo in lowering SSBP at endpoint (Table 2 ). There were no statistiTolerability and safety cally significant differences between active treatment groups at endpoint, with the exception of a
The overall frequency of adverse experiences, regardless of relationship to trial medication, was small difference between the lisinopril 10/20 once daily and valsartan 80/80 twice daily group (P = similar for those taking valsartan (all doses, 62.6%), lisinopril (all doses, 58.3%) and placebo (63.4%). 0.011). However, the small difference in SSBP in favour of lisinopril but with comparable SDBP When individual dose groups were compared the frequency was also comparable between the groups reduction is unlikely to be of major clinical relevance.
(valsartan 80 mg, 45.3%; lisinopril 10 mg, 45.5%; valsartan 160 mg, 49.2%; lisinopril 20 mg, 50.0%). The percentage of 'successful' responders was significantly superior for all active treatment groups Table 4 shows the frequency of adverse experiences considered trial drug related. More cases of compared to placebo at all time points (P Ͻ 0.001) treatment due to cough in the valsartan or the placebo groups.
Of the adverse experiences that led to discontinutrial drug related adverse experiences were reported ation of therapy and were judged by the investigator in those taking lisinopril (all doses: 27.8%) than valto be at least possibly related to trial treatment, sartan (all doses: 22.8%) or placebo (19.1%). For lisseven cases occurred with valsartan (three patients inopril there was a slightly higher incidence of drug with headache, one lightheadedness, one shortness related adverse experiences with the 20 mg dose of breath, one rash, one fatigue); six cases with lisin-(24.2%) compared to 10 mg (19.3%). For valsartan opril (three patients with cough, one chest pain, one no such dose related increase was seen with 15.7% nausea/dizziness, one fatigue) and six cases with of volunteers reporting a drug related adverse placebo (four patients with headache, one vomiting, experience on valsartan 80 mg compared to 14.3% one fatigue). on valsartan 160 mg. The most frequently reported Sitting and standing pulse and body weight movetrial drug related adverse experience in the valsartan ments did not show any clinically significant differand placebo treatment groups was headache and ences between treatment groups at any time points. fatigue (7.7% headache, 2.2% fatigue for valsartan Upon review of orthostatic changes in BP, physiall doses; 9.3% headache, 1.6% fatigue on placebo; cal examination findings, group mean values for 3.2% headache, 3.7% fatigue for lisinopril all haematology and chemistry laboratory values, fredoses).
quency distribution of changes from baseline to labFor lisinopril the most frequently reported drug oratory values at endpoint and individual laboratory related adverse experience was cough. Trial drug related cough occurred more frequently in lisinopril values during the double-blind treatment period, no clinically important trends were observed for any of staff without whom the present study would not have been possible. the parameters assessed.
